Expanding to the world market
Emotional Brain announced in its press statement that the company has had positive and productive meetings with the FDA to discuss the results of the clinical studies of Lybrido and Lybridos. The next phase of bringing the drugs to the American and European markets is set to begin in 2014. Both drugs are innovative in the way that they are examples of a personalised approach to the treatment of physical problems. In this case, the drugs are designed for women with a relatively insensitive brain system for sexual signals.
Amsterdam’s well-developed medical sector
The work of Emotional Brain is an indication of the quality and innovation of the well-developed medical sector in the Amsterdam Metropolitan Area. The area hosts the highest concentration of life sciences research in the Netherlands, with more than 20,000 employees and a strong focus on biomedical and human health. It is expected that the combination of expertise in different areas will attract additional talented researchers and specialists, thereby increasing the critical mass of knowledge workers in the medical sector.